Loading…

Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution

Introduction: The present study evaluates CD30 expression by immunohistochemistry (IHQ) in 216 patients with de novo DLBCL. Methods: CD30 expression was assessed retrospectively in all cases by IHQ. More than >0% and >20% of CD30 expression in the malignant cells were used as a cut-off for pos...

Full description

Saved in:
Bibliographic Details
Published in:Biomarkers 2020-01, Vol.25 (1), p.69-75
Main Authors: Salas, María Queralt, Climent, Fina, Tapia, Gustavo, DomingoDomènech, Eva, Mercadal, Santiago, Oliveira, Ana Carla, Aguilera, Carmen, Olga, García, Moreno Velázquez, Miriam, Andrade-Campos, Marcio, Encuentra, Maite, Fernández de Sevilla, Alberto, Sureda, Anna, Sancho, Juan Manuel, González-Barca, Eva
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: The present study evaluates CD30 expression by immunohistochemistry (IHQ) in 216 patients with de novo DLBCL. Methods: CD30 expression was assessed retrospectively in all cases by IHQ. More than >0% and >20% of CD30 expression in the malignant cells were used as a cut-off for positivity. Survival was analysed in 176 patients treated with R-CHOP/R-CHOP-like regimens. Results: CD30 expression >0% was found in 66 (31%) patients, and >20% in 41 (19%). Younger patients
ISSN:1354-750X
1366-5804
DOI:10.1080/1354750X.2019.1691656